In therapeutic terms, Dmab, an anti-RANKL medication approved for the treatment of osteoporosis, may also prove suitable in the future for the treatment of metabolic diseases, e.g., obesity, T2DM, and NAFLD. Here, TNFSF11 is linked to obesity due to melanocortin 4 receptor deficiency.